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Abstract  
Data on chronic Hepatitis C (HCV) infection prevalence in European prisons is incomplete and 
impacts the public health opportunity that incarceration provides. 
Aims  
We aimed to estimate the seroprevalence of untreated chronic HCV infection and to identify 
associated risk factors in an Irish prison 
Methods 
We conducted a cross sectional study involving a researcher-administered questionnaire, review of 
medical records and HCV serology.  
Results  
422 prisoners (78% of the study population) participated in the study of whom 298 (70.6%) 
completed the questionnaire and 403 (95.5 %) tested for HCV antibody. Of those tested, 92 (22.8%) 
were HCV antibody positive of whom, 53 (57.6%) were HCV RNA positive, 23 (25%) had spontaneous 
clearance, 16 (17.4%) had a sustained viral response, 10 (11%) were co-infected with HIV and 6 (6%) 
with HBV. The untreated chronic HCV seroprevalence estimate was 13.1% and the seroprevalence of 
HCV among prisoners with a history of injecting drug use (IDU) was 79.7%. 
Risk factors significantly associated with HCV acquisition were IDU (p<0.0001), having received a 
prison tattoo(p<0.0001) or a non-sterile community tattoo (p<0.0001), sharing needles and other drug 
taking paraphernalia (p<0.0001). Sharing of razors (p=0.95) and toothbrushes (p= 0.32) while 
incarcerated were not significantly associated with HCV acquisition. On multivariate analysis, a 
history of receiving a non-sterile community tattoo was the only significant risk 
factor associated with HCV acquisition (after IDU was removed from the model) (p=0.005, 
β=0.ϰϲϴͿ.  
Conclusion 
The level of untreated chronic HCV infection in Irish prisons is high, with IDU the main associated 
risk.  
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Introduction  
Hepatitis C Virus (HCV) infection is a major public health concern and is a leading cause of liver related 
morbidity and mortality globally [1]. There are an estimated 5.6 million people (1.1 % of the 
population) living with chronic HCV infection in the European region [2]. In Europe, including Ireland, 
injecting drug use (IDU) is the major driver of this blood borne infectious disease [3–5].  
It is accepted that people who inject drugs (PWID) and HCV infection are typically over-represented in 
prison populations across Europe [6,7]. A recently published systematic review reported a prison HCV 
prevalence in Western Europe of 15.5% (CI, 12.2–19.1), with this prevalence increasing to over 40% 
among those prisoners with a history of IDU [3]. Despite prisoners being identified as a key at-risk 
group for HCV infection, epidemiological data on the extent of the prison HCV burden is incomplete, 
out of date and in some European countries, non-existent [6,8]. Most epidemiological studies in 
people who inject drugs (PWID) and prisoners report on HCV antibody prevalence (exposure) and not 
on HCV RNA infection (chronic) [6,9,10].  Where HCV-RNA prevalence is reported it is often on subsets 
of prisoners and published studies do not differentiate between treated chronic infection with 
sustained viral response (SVR) and the 20-30% of HCV infected people who spontaneously clear HCV 
without treatment [11] .    
Of the 600,000 people incarcerated in the EU/EEA at any given time, 3,400 are in prisons in Ireland 
[12] . A 2000 study estimated the prevalence of HCV infection in the Irish prison population at 37% 
increasing to 81% % among those with a history of IDU [13]. A later study (2014) reported a HCV 
prevalence of 13% [9]. This reducing trend is in keeping with a recognised global reduction in prison 
HCV prevalence and may in part be due to the expansion of Irish community and prison-based harm 
reduction services[6,9].There is no systematic approach to HCV screening in Irish prisons and only 
three Irish prisons (including the study location) have specialist in-reach hepatology services. Despite 
national and international guidelines recommending HCV screening for all prisoners and a community 
equivalence of care in relation to HCV treatment access, most Irish prisoners are not screened, 
assessed or treated for HCV infection [14–16].  
This study aims to estimate the levels of untreated chronic HCV infection and associated risk factors 
for acquisition in an Irish prison population. It updates previous prevalence studies and is unique both 
nationally and internationally in reporting genotype distribution and estimating levels of untreated 
chronic infection in a prison population. 
 
Methods 
This study is reported in accordance with the Strengthening the Reporting of Observational studies in 
Epidemiology guidance (STROBE) [17]. Ethical approval for the research was granted by The Mater 
Misericordiae University Hospital Research Ethics Committee and the Irish Prison Service (IPS) Ethics 
Review Committee. 
The Irish Prison Service (IPS) partnered with the European Commission Third Health Programme 
fuŶded ͚HepCare͛ ProjeĐt [18] to enhance screening for populations at risk of HCV infection, and 
specifically implementing an enhanced HCV screening programme at Mountjoy prison in Dublin, 
Ireland. Mountjoy Prison is a large urban prison which at capacity houses 538 sentenced male 
prisoners. The mean age of prisoners incarcerated at this location is 34 years , with a third serving 
sentences of less than 12 months and almost a half on restricted regimes (protection 
prisoners)[12,19]. 
The programme consisted of an initial nurse-led screening programme followed by a peer-supported 
mass screening initiative. The Irish Red Cross trains a network of prison volunteers in basic community 
and public health across the IPS. Volunteers incarcerated at the study location collaborated in the 
design and implementation of this initiative which began in early 2017 and due to staffing and 
logistical issues required a six-month period to complete.  
All prisoners were offered screening for blood borne viruses (BBV), including reflex RNA testing and 
genotyping. Reflex RNA testing is the automatic RNA testing of HCV Ab +ve samples without the need 
for a further request or repeat blood test. 
First line serological screening for HBV, HCV and HIV viruses was carried out using chemiluminescent 
microparticle immunoassays on the Architect i4000sr automated platform. Confirmatory testing of 
reactive samples was carried out using alternative assays. HIV serological diagnosis was based on the 
Abbott Architect HIV Ag/Ab Combo and confirmatory testing for reactive samples using the VIDAS HIV 
DUO Ultra (BioMérieux) and HIV INNO-LIA HIV I/II Score (Innogenetics) assays. The Abbott Architect 
assays were used for HBV associated markers and to characterize the HBV infection status. Serological 
screening for HCV included the anti-HCV test (Abbott Architect), a third-generation immunoassay and 
the HCV Ag (Abbott Architect) assay. All anti-HCV reactive samples with negative HCV Ag were further 
investigated to confirm the presence of anti-HCV using the anti-HCV VIDAS (BioMérieux) and INNO-
LIA HCV Score (Innogenetics) assays. When HCV was confirmed serologically, molecular detection of 
HCV RNA was performed using the Abbott RealTime HCV assay. HCV genotyping was conducted on 
samples with detectable HCV RNA using the Abbott RealTime HCV Genotype II assay.  
For this study SVR was defined as HCV-RNA negative at 24 weeks post completion of interferon-based 
treatment and 12 weeks for DAA treatment. Chronic HCV infection was defined as ongoing active 
infection (HCV RNA +ve) six months after initial exposure. A medical chart review of historical serology 
and HCV risk history was conducted on prisoners testing HCV ab+. This allowed the HCV serology to 
be interpreted as infection with self-clearance, infection with SVR and untreated chronic infection. 
This information was cross- checked with the prisoner for accuracy. 
Data on variaďles ǁas ĐolleĐted froŵ tǁo sourĐes; prisoŶers͛ eleĐtroŶiĐ ŵediĐal reĐord stored oŶ the 
Prison Health Management System (PHMS) and a researcher-administered questionnaire. All 
prisoners routinely complete a nurse committal interview on the day of incarceration which is stored 
iŶ the prisoŶers͛ ŵediĐal reĐord oŶ the PHMS. From this medical review the following variables were 
collected, age, country of origin, history of drug and alcohol use, presence of visible injecting marks 
and history of sharing needles. 
The questionnaire was developed and piloted by the research team in conjunction with national 
experts in the area and prisoner groups. The questionnaire included questions on age, country of 
origin, incarceration history, pre-incarceration accommodation, drug use, IDU history including history 
of sharing needles and drug taking paraphernalia, history of tattooing, sharing of tooth brushes and 
razors while incarcerated and self-declared risk for HCV infection. Questionnaires were completed as 
part of screening but priority was given to screening, particularly in areas of the prison that housed 
enhanced security prisoners. 
All prisoners incarcerated on 31/3/17 were eligible for inclusion in the study except those considered 
to have severe mental illness undergoing active treatment and prisoners considered to pose a security 
risk to the research team. All study participants were given a patient information sheet and asked to 
sign a consent form. No inducements were offered. 
All data was anonymized and coded, double entered and checked. Statistical analysis was performed 
using the Statistical Package for Social Sciences (version 23.0; SPSS UK Ltd.; Chersey, UK). Data were 
assessed for normality and where necessary, data were log-transformed for normalisation purposes. 
Data within tables are primarily expressed as means (SD) or n (%). Categorical variables were assessed 
by chi-square analysis while nominal variables were assessed by Independent T-test. Linear regression 
analysis adjusted for a history of IDU was used to identify predictors of exposure to HCV infection. 
Results 
Demographic data 
A total of 538 men were incarcerated on the day of the study, of which 13 were excluded on mental 
health grounds, 58 refused to consent for the research, 24 were released and 21 transferred to 
another prison before engagement in the study. A total of 422 (78% of the study population) 
participated in the study (see Figure 1). Committal interview data was available on 422 participants, 
404 (95.7% of study participants) completed screening with 298 (73.8% of those screened) completing 
some or the entire risk questionnaire (fig 1).  
The median age of the study population was 33.3 years, 394 (93.4 %) were Irish and the remainder 
came from numerous other countries. There were no statistical differences for age and country of 
origin between the entire prison population and study recruits. On committal interview (n=422), 
almost half admitted to a history of drug use (49.3%), 27(6.4%) had visible active injecting sites and 30 
(7.1%) reported a history of sharing needles. 
Data from the questionnaire showed a mean age at first incarceration of 19.6 years, with the mean 
number of incarcerations being 5.9 years and a total mean time spent in prison of 8 years. The mean 
age of first drug use, heroin use and IDU were 15.3 years, 19.5 years and 20.5 years respectively. Of 
those prisoners who completed questions on HCV risk factors, 134 (46.7%) gave a history of heroin 
use, 90 (32.6 %) a history of IDU, 44 (15.9%) admitted to sharing needles and 104 (37.4%) to sharing 
drug taking paraphernalia. 48 reported having a tattoo in prison (16.5%) and having a non-sterile 
tattoo in the community (16.0%). Only 10 prisoners (3.4%) reported sharing razors and 3(1%) a tooth 
brush. 96 prisoners (34.7%) reported ever engaging with methadone maintenance treatment (MMT) 
with the mean length of time on treatment being 6.2 years (table 1). 
BBV status  
Of the 422 study participants, 404 (95.7 %) had a screen for HIV, 403 (95.5 %) for HBV and HCV 
infection showing a prevalence of 4%, 3% and 23.8% respectively. 10 (11%) HCVab+ prisoners were 
co-infected with HIV and 6 (6.6 %) with HBV. Prisoners with a history of IDU had an HCV ab+ prevalence 
of 79.7%.   
Of the 92 HCV ab+ prisoners, 23 (25%) had spontaneous clearance, 16 (17.4%) had an SVR post -
treatment and the remaining 53 (57.5%) had chronic untreated infection. This reflects a chronic 
untreated HCV infection prevalence of 13.2% among those tested (Table 1).  
Genotyping was available for 63 (50 from screening and 13 from medical records) of those with chronic 
infection (treated and untreated) with 37 infected with Genotype 1A and 26 with Genotype 3 (Table 
1). 
 
Associations 
On comparative analysis there were significant difference between those HCVab+ compared to those 
who were not. HCVab+ prisoners were older (p< 0.0001), had increased episodes of incarceration (p< 
0.0001), had spent twice as long in prison (p< 0.0001) and were significantly younger at age of first 
heroin use (p= 0.0003) and IDU (p= 0.015). Stability of pre-incarceration accommodation was a factor 
in HCV status, with those experiencing homelessness more likely to be infected (p=0.001). Country of 
origin did not appear to impact on HCV status with no statistical differences seen between Irish and 
non-Irish prisoners (p=0.593). 
HCVab+ prisoners were significantly more likely to have a history of drug use (p=0.001), heroin use, 
IDU, sharing needles, and drug taking paraphernalia in the community (p<0.0001). HCV ab+ prisoners 
were more likely to have had a prison tattoo (p <0.0001) and an unsterile community tattoo (p=0.024).  
A pre-incarceration history of, and treatment for, alcohol misuse problems did not impact on 
prisoŶers͛ HCV status ;p= 0.2ϴͿ ;p=0.ϲϳͿ. HCV aď+ prisoŶers ǁere sigŶifiĐaŶtly ŵore likely to haǀe a 
history of MMT (p<0.0001).  
On preliminary multivariant analysis (including IDU) none of the above risk factors were shown to be 
independent risk factors for HCV infection (supplement 2). When IDU was excluded only non-sterile 
tattoo iŶ the ĐoŵŵuŶity reŵaiŶed aŶ iŶdepeŶdeŶt risk faĐtor. ;p= 0.00ϱ, CI aŶd β= 0.ϰϲϴͿ ;Taďle ϰͿ 
 
Discussion 
This study found a general prison population HCV ab+ prevalence of 22.8% in an Irish male prison 
increasing to 79% among prisoners with a history of IDU. A quarter of the HCV exposed cohort had 
spontaneously cleared the virus and 17.4% had an SVR post-treatment. Reflex RNA testing showed 
that 57.3% of HCV exposed prisoners had untreated chronic infection represented a general prison 
population prevalence of chronic untreated HCV infection of 13.1%. The major risk for HCV acquisition 
was IDU (P< 0.0001). This study found low levels of self-reported tooth brush and razor sharing and 
these were not found to be risk factors for HCV acquisition.  
The HCV ab + prevalence (22.8%) in this study is comparable  to that reported in a review estimating 
the prevalence among prisoners globally[6]. It is higher than the 13 % reported in the last Irish prison-
based HCV prevalence study [9]but lower than the 37% reported in the earlier 1999 study [13]. Both 
these studies were multi-site national studies which included most of the fifteen prisons in Ireland. 
The downward trend from the 2000 study is supported by the findings of the global 2014 systematic 
review and more recent European review which found that older studies reported higher prevalence 
rates [3,6].    
The upward trend since the 2014 study could be explained by the fact that this is a single site study, 
in a prison considered to have moderate to high levels of PWID among its prison population and 
consequently would be expected to have a higher HCV disease burden [9,13]. This finding also 
underpins the inter-prison and regional variation in HCV prevalence that occurs within and between 
countries and the need for accurate and institution specific data when planning and resourcing prison-
based HCV treatment services [6,9,13]. This HCV prevalence estimate reflects a rate 50 times higher 
than the estimated HCV prevalence in the general Irish population[20]. 
There is marked regional variation and extensive gaps in the data on the size of the active HCV disease 
burden in prisoners [6]. As previously noted, most prison-based prevalence studies report on HCV 
exposure rather than active infection [6,9]. Of those exposed, 20-30% will spontaneously clear the 
virus and the remainder will progress to chronic infection, which is measured by the presence of HCV-
RNA in the blood after 6 months post the acute infection [21]. This study found a spontaneous 
clearance of 25 % similar to previously published studies [1,21,22].  
This Irish study found that 23.2 % of those with chronic infection had been successfully treated with 
SVR and no re-infections to date. This level of treatment is high when compared to other reported 
studies and may reflect the impact of an in- reach hepatology service at this site for many years 
[23,24]. This finding also supports the existing evidence that PWID and prisoners can be successfully 
treated for HCV infection [25,26]. The absence of re-infection among those showing SVR post 
treatment is contrary to published evidence showing high levels of re-infection among prisoners [27].   
This may in part be due to the high levels of OST in Irish prisons. A Scottish study reported that 
incarceration was protective against HCV transmission because of the high levels of OST coverage in 
Scottish prisons [28]. 
In the interferon-based HCV treatment era the levels of HCV treatment in PWID and prisoners were 
so small that HCV ab+ prevalence data, mathematically modeled to allow for spontaneous clearance, 
was reflective of the untreated chronic HCV disease burden [6]. With the new DAA therapies many 
countries are engaging significant numbers of prisoners and PWID in treatment with high compliance 
and SVR rates [29–31] Studies that report on HCV-antibody levels in populations do not distinguish 
between self-clearance and SVR post treatment [11,32] and miss the impact of treatment and rates of 
re-infection[11,32]. This unique study demonstrates how more detailed HCV surveillance data can 
more accurately estimate the HCV disease burden in a population.  
As previously outlined, drug users and PWID are over represented in prison populations globally [6,9]). 
This study reports similar findings with half of prisoners admitting to drug use and a third to a history 
of IDU. In this prison cohort, drug use began early (15.5 yrs.) with progression to heroin by (19.5 yrs.) 
and to IDU by (20.4 yrs.). High levels of risk behaviour related to drug use was also reported with 15.9 
% reporting sharing a needle and 37.4 % reporting sharing other drug taking paraphernalia. These 
findings reflect the stark reality of drug use and risk behaviour in this marginalised cohort and indicate 
that prevention strategies are needed from a very young age.  
A number of HCV transmissions risks in prisoners have already been reported in the literature these 
include IDU, prison tattooing, and factors independent of these but linked to incarceration such as 
violent assault, sharing of tooth brushes and razors and possibly other unidentified factors [6,9,33,34]. 
There is also evidence in the literature of increased HCV transmission among HIV -infected men who 
have sex with men (MSM), which is a concern in prisons without access to condoms [35]. Previous 
studies have reported high HCV prevalence among prisoners coming from countries of high HCV 
endemicity [6,33,36].  
This study reports similar findings with IDU being the major risk factor for HCV infection. Prisoners 
reporting a history of IDU had an 80% prevalence for anti-HCV. A number of other variables (age, 
homelessness, length of time on methadone, length of time and numbers of times incarcerate the 
sharing of non-needle drug taking paraphernalia and prison tattooing) where statistically associated 
with HCV exposure, however, on multi-variant regression analysis were not found to be independent 
of IDU. This suggests that prisoners with a history of IDU have multiple HCV risks and that any planned 
HCV prevention strategies will need to target all these factors [6,33,35,37]. 
Being older has previously been reported as a risk factor for HCV infection [6,9,34]. We report similar 
findings for age but found that this was not independent of IDU. Again, this is expected given that 
older prisoners have longer histories of IDU with an elevated risk of potential HCV exposure over time. 
The finding that the vast majority of prisoners do no share tooth brushes or razor is encouraging and 
certainly in an Irish context eliminates these as sources of HCV transmission. This study shows that 
being non-Irish in this prison population was not associated with HCV exposure. However, the 
numbers were small and had to be categorised for reporting in a way that protected anonymity.  
Clearly targeting prisoners with a history of IDU for active HCV case finding is a priority given the high 
HCV prevalence rates in this group[7]. It is also important to recognise that prisoners will under report 
IDU because of fear of stigma and discrimination [6,9,11]. The move away from risk based to opt-out 
prison-based HCV screening is addressing this issue in some jurisdictions and has the potential to be 
adapted by the IPS to increase screening uptake among Irish prisoners [38,39].  
The 78% participation is a major strength of this study. Previous Irish HCV prevalence studies found 
the prisoners in this particular prison difficult to engage and had much poorer uptake [9]. These 
studies were randomised in design and did not include the entire population. The use of serum 
samples rather than historical BBV screening data from chart records is unusual in these types of 
studies and with high levels of both sensitivity and specificity for this method offers increased validity 
to this study over those using saliva samples [9,13].  
The use of a research-completed questionnaire has both strengths and limitations. The two previous 
Irish studies used self-completed questionnaires. The design of the study allowed researchers to spend 
time with the prisoner and to add clarification regarding the meaning/interpretation of the questions. 
While overcoming the issue of literacy it was time consuming which impacted on completion rates. 
There are a number of limitations to this study. It is single site and only includes male prisoners, 
making the findings more difficult to generalise both nationally and internationally. The study design 
was deigned to allow for its implementation in a real-life prison setting and for it to be both a health 
intervention (HCV screening) and a research study measuring HCV prevalence. The dynamic nature 
of prison populations (releases, inter-prison transfers and short sentences) makes cross sectional 
epidemiological studies difficult to implement.   
The self-reported nature of the data is a limitation. We did not receive ethical approval to retrieve 
data oŶ study partiĐipaŶts͛ iŶĐarĐeratioŶ history from their electronic prison records so had to rely on 
self-report for these variables which may be prone to bias. The researcher completing the 
questionnaire was unknown to the prisoners which may have allowed for more open and frank 
disclosure of risk behaviour. The engagement of non-clinical staff was essential in carrying out this 
study. Hoverer there were limits on allocated time to access prisoners consequently screening was 
prioritised over the completion of the risk questionnaire. This was particularly an issue in parts of the 
prison that contained protection prisoners where enhanced security measures were in place meaning 
less access to prisoners.   
Conclusion 
This study reports an anti-HCV prevalence of 22.8%, with an untreated chronic HCV prevalence of 13.2 
% in a male Irish prison population. The identified genotype distribution was 58% for genotype 1A and 
42% for genotype 3A. The main risk for HCV infection was IDU but there was also a statistically 
significant association with prison tattooing, non-sterile community tattooing, the sharing of needles 
and other drug taking paraphernalia, older age and pre-incarceration homelessness. The sharing of 
tooth brushes and razors or not having Ireland as a country of origin were not associated with HCV 
exposure. The reporting of HCV infection in prisoners in this way is unique in both the Irish and 
international literature and allows for the estimation of the true levels of active HCV infection, the 
monitoring of treatment outcomes and rates of re-infection. Identifying risk factors for HCV infection 
allows for targeted prevention, screening and treatment strategies. Combined they allow for the 
informed planning and implementation of national and international HCV strategies.  
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